Bayer's Pharma Arm Does the Heavy Lifting as Write-Downs and Litigation Keep the Bottom Line in the Red

Bayer's prescription-drug unit delivered the kind of quarter that gets a stock moving, and investors responded accordingly: the shares climbed 4.0% today after the German group reported third-quarter 2026 results. Yet the same set of figures also laid bare how uneven the recovery remains, with a net loss of EUR 672 million and a fresh round of impairment charges keeping the headline number deep in negative territory.

The impairments totaled EUR 522 million and were booked against Xofigo and Claritin, two products whose carrying values no longer match their prospects. That charge explains the gap between the adjusted operating picture and the bottom line — and it is the reason a stronger trading performance has not yet translated into a positive group result.

Earnings growth outpaces sales at group level

Group revenue for the three months came in at EUR 10.053 billion, up 4.1% year on year. EBITDA before special items advanced 6.9% to EUR 1.615 billion, meaning profit grew faster than the top line. Those are respectable numbers on their own, but they sit alongside the net loss rather than replacing it.

The pharmaceutical division was the engine behind that operating improvement. Sales there rose 8% to EUR 4.68 billion, while EBITDA before special items jumped 23.6% to EUR 1.292 billion — a pace of earnings growth well ahead of revenue. The unit's margin reached 27.6%, and management credited the division with driving much of the improvement seen across the group.

Within the portfolio, the handover from old to new is now clearly visible. Nubeqa and Kerendia posted currency- and portfolio-adjusted growth of 58.3% and 64.9% respectively, while Xarelto and Eylea saw meaningful declines. The newcomers are not merely adding revenue; they are generating enough profit to offset the erosion of established products whose patents are running out.

Agriculture drags, and the balance sheet stays stretched

Not every division contributed. Adjusted EBITDA at Crop Science collapsed 41.3% to EUR 101 million, with Bayer pointing to regulatory factors and weather effects in the agricultural business. That weakness puts additional weight on pharmaceuticals, which must now compensate for softness elsewhere in the group as well as for its own patent expirations.

Management raised its full-year 2026 guidance on the back of the quarter. Group EBITDA before special items is now expected at EUR 9.8 billion to EUR 10.3 billion, and the margin target for the pharmaceutical division was lifted to 25% to 27%. The free-cash-flow forecast improved by EUR 1.0 billion, though it remains negative at minus EUR 1.5 billion to minus EUR 0.5 billion — a reminder that the cash register is still running in reverse.

Net financial debt at year-end is projected at EUR 28.0 billion to EUR 29.0 billion.

Litigation is no longer a glyphosate-only story

Legal exposure continues to cloud the picture. Business Insider reported yesterday on PCB claims stemming from the Monsanto acquisition, for which Bayer has already set aside billions. CEO Bill Anderson expects further proceedings in the coming quarters. The significance is that the risk is not confined to glyphosate: even progress on that front would leave the remaining litigation burdens untouched.

JPMorgan reaffirmed its "Overweight" rating on Bayer following the results, keeping a price target of EUR 61.

For shareholders, the takeaway is that the operating turnaround is real but incomplete. The question that matters now is whether growth from new medicines can survive write-downs and legal payouts to reach the group's net result — or whether the gap between adjusted strength and reported losses persists.